I have enough to write. Here is the investigation.

---

The Federal Law Requiring States to Watch Who Drugs Foster Kids Is in the Wrong Title of the Social Security Act — and Nobody Has Ever Been Penalized for Ignoring It

For fifteen years, the federal government has known that children in foster care are given powerful psychiatric drugs at multiples of the rate of other poor children — including infants under a year old, children on five or more psychotropics at once, and children dosed above the maximum levels on the FDA label. It has said so in its own reports, repeatedly, since 2011. Congress responded by writing an oversight mandate into law. But that mandate was placed in Title IV-B of the Social Security Act — a small, capped grant program — rather than Title IV-E, the open-ended entitlement that actually pays states billions of dollars to hold children in foster care. The result is a legal duty with no financial consequence attached to breaking it. In March 2026, HHS's own Inspector General opened a new investigation whose stated premise is that a decade after it found one in three medicated foster children were not being monitored as required, "high rates of psychotropic medication use among children in foster care remain concerning."

The mandate, and the reason it does nothing

The requirement is real and it is specific. Section 422(b)(15) of the Social Security Act — codified at 42 U.S.C. § 622(b)(15) — requires every state, as a condition of its child welfare services plan, to describe a coordinated strategy for the health care needs of children in foster care, including "an outline of the oversight of prescription medicines." The Child and Family Services Improvement and Innovation Act of 2011 (P.L. 112-34, § 101) added the health-oversight plan — and with it, specifically, the requirement of protocols for the appropriate use and monitoring of psychotropic medication. (The Supporting America's Children and Families Act, P.L. 118-258, § 106(e)(4), enacted January 4, 2025, later strengthened that clause with informed-consent and professional-practice-guidelines language, effective October 1, 2025 — while leaving it in Title IV-B.)

Here is the structural defect at the center of this story. Section 422 is Title IV-B, subpart 1 — the Stephanie Tubbs Jones Child Welfare Services program, a comparatively small capped formula grant. It is not Title IV-E, the open-ended entitlement under which the federal government reimburses states for a share of every eligible child's foster care maintenance, administrative costs, and case management, and which moves billions of dollars a year.

That distinction is the whole ballgame. Title IV-E compliance is policed through federal reviews with real money at stake; a state that loses IV-E eligibility loses its largest child welfare revenue stream. Title IV-B compliance is policed by asking the state to describe its plan in a document. A state that files a psychotropic oversight protocol and then never implements it has satisfied the statute as written. The oversight requirement was attached to the small grant, and the money was left in the big one — and the big one pays states more when a child is in care, not when a child is well.

How the machine actually works

A child is removed. Up to 80% of children entering foster care arrive with significant mental health needs, according to the HHS Office of Inspector General — trauma, neglect, disrupted attachment, the removal itself. That need is real and it is not in dispute.

What happens next is where the system breaks. The child is placed, often with a stranger, sometimes in a group home or residential treatment facility. The child behaves the way traumatized children behave: rages, tantrums, defiance, sleeplessness, running. A placement is at risk. A caregiver or facility asks for something to make the behavior stop.

The child is Medicaid-eligible by virtue of being in IV-E foster care. A prescriber — frequently not a child psychiatrist, frequently with a fifteen-minute appointment and no access to the child's real history — writes for an antipsychotic. Consent is obtained from whoever the state says can give it: a caseworker, an agency medical consenter, a court, sometimes a parent whose rights have not been terminated but who has not been located. In many states, no single human being with a durable relationship to the child ever reviews the whole medication list.

There is no continuity. Foster children move; their records don't. The federal audits below are, at bottom, audits of a system that cannot reliably say what drugs a child is on.

The numbers HHS has published about itself

GAO, December 2011 (GAO-12-201). Reviewing 2008 Medicaid data in Florida, Massachusetts, Michigan, Oregon and Texas, GAO found foster children were prescribed psychotropic drugs at rates 2.7 to 4.5 times higher than non-foster children on Medicaid. GAO also found:

• Infants. Children under one year old were prescribed psychotropics — drugs GAO's expert panel said have no established use for mental health conditions in infants. The rate ran 0.3% to 2.1% among foster infants versus 0.1% to 1.2% among non-foster infants: 76 foster babies in five states.
• Polypharmacy. GAO's experts stated that no evidence supports the concomitant use of five or more psychotropic drugs in adults or children. Hundreds of children in those five states were on exactly that.
• Dosing. Thousands of children were prescribed doses above the maximum levels in guidelines Texas built from FDA-approved labels.

HHS OIG, March 2015 (OEI-07-12-00320). OIG reviewed 687 claims for second-generation antipsychotics prescribed to children in California, Florida, Illinois, New York and Texas — states representing roughly 39% of all Medicaid SGA payments in 2011. The finding: only 8% of those antipsychotic prescriptions were for a medically accepted pediatric indication. Ninety-two percent were not. More than a third were written for children whose condition matched an FDA boxed warning. One child in the sample developed akathisia — a torturous movement disorder. Another experienced hallucinations, paranoia and suicidal ideation while on a regimen of six psychotropic drugs, three of them antipsychotics. OIG told CMS to run utilization reviews, do periodic medical-record reviews, and consider peer review. CMS concurred with all three.

HHS OIG, September 2018 (OEI-07-15-00380). In the five states with the highest psychotropic utilization in foster care, one in three medicated foster children received neither treatment planning nor medication monitoring as required by their own state's rules. Not federal rules — the states' own. The recommendation that ACF develop a comprehensive strategy to fix state compliance was not closed as implemented until January 30, 2026 — more than seven years later.

Where the drugs land. National survey data show roughly 18% of foster children on a psychotropic and about 6.4% on an antipsychotic, but the distribution is not flat. Children in group homes and residential treatment centers: 48%. Non-relative foster homes: 14%. Kinship care: 12%. The drugs concentrate exactly where a paid facility, not a family, controls the day. Foster youth are roughly five times more likely to be on an antipsychotic than children in the general population. Antipsychotic use among foster children has ranged from 2.8% to 21.7% depending on which state you happen to be removed in — an eightfold spread that no clinical theory explains.

The money

Medicaid pays for the drugs. Because IV-E foster children are categorically Medicaid-eligible, the prescription is nearly always covered. Federal Medicaid dollars flowed to the 92% of pediatric antipsychotic prescriptions OIG found lacked a medically accepted indication. That is not a coverage gap — that is the federal government financing the practice it is simultaneously auditing.

Title IV-E pays for the placement. The federal reimbursement follows the child into care. It does not follow the child into a stable home, and — before the Family First Prevention Services Act — it flowed freely to congregate care, the setting with 48% psychotropic use.

The residential operators. This is where the incentive becomes visible in dollars.

• Universal Health Services (NYSE: UHS), the largest operator of behavioral health facilities in the country, paid $122 million in July 2020 to resolve False Claims Act allegations — including $117 million to the United States and participating states — over medically unnecessary inpatient behavioral health admissions, failure to provide adequate services, and improper use of restraints. The case consolidated 18 whistleblower suits; relators collected $16.7 million. UHS accepted an independent monitor selected by the HHS OIG.
• Acadia Healthcare (NASDAQ: ACHC) paid $19.85 million in September 2024 — $16.5M federal, $3M+ to Florida, Georgia, Michigan and Nevada — over conduct from 2014 to 2017: admitting beneficiaries who did not qualify for inpatient care, failing to discharge them when they no longer needed it, running excessive lengths of stay, and failing to produce adequate treatment plans. Named facilities included Park Royal Hospital and North Tampa Behavioral Health (FL), Lakeview Behavioral Health and Riverwoods (GA), Harbor Oaks (MI), and Seven Hills Hospital (NV).

Neither settlement was specifically about drugging foster children. Both are about the same underlying economics: a bed is a revenue unit, a compliant child is a cheaper bed, and the government pays either way.

The nonprofit side. Project Milk Carton's federal award database shows The Devereux Foundation — one of the nation's largest nonprofit behavioral health and residential providers for children — has drawn roughly $91.8 million in federal awards on record, including a $48.2 million HHS award (CFDA 93.566) in the FY2022 period and $30.4 million under CFDA 93.676, the Unaccompanied Children program. Devereux has been a defendant in litigation reaching state high courts, including Taylor v. Devereux Foundation, 316 Ga. 44 — the Georgia Supreme Court decision arising from an assault at a Devereux facility — and remains in active Florida appellate litigation (D.L. v. Community Based Care of Brevard / Devereux Florida, Fla. 5th DCA, decided February 13, 2026). The point is not that nonprofit status makes an operator innocent. It is that "nonprofit" and "for-profit" congregate care draw from the same federal spigot and face the same incentive.

The pharma playbook that built the prescribing habit

The prescribing patterns did not arise spontaneously. They were engineered.

The Texas Medication Algorithm Project (TMAP) was a state prescribing protocol that steered clinicians toward newer, patented antipsychotics. Pharmaceutical companies subsidized TMAP to the tune of roughly $1.3 million, more than half of it from Johnson & Johnson and Pfizer. TMAP was then exported to other states as a model.

Allen Jones, an investigator in the Pennsylvania Office of Inspector General, began asking how his state had adopted a protocol favoring Janssen's Risperdal. He was forced out of his job. He became a whistleblower.

Texas's Attorney General sued Janssen, alleging it marketed the antipsychotic for use in children when the drug was approved only for the narrow purpose of treating adult schizophrenia — a drug known to cause severe weight gain and diabetes, with particular severity in children. In January 2012, Janssen settled with Texas for $158 million.

That is the origin story of the off-label pediatric antipsychotic. A patented drug, a state prescribing algorithm bought and paid for, a captive Medicaid population, and a set of children with no parent in the room.

What the audits keep finding — state after state

Since 2020 the HHS Inspector General has audited state child welfare medication records one state at a time. The results are not close calls.

• Indiana (A-05-21-00020): of 115 sampled children, 109 had no medical passport in their health record; 76 had psychotropic or opioid medications that were never recorded in the state's MaGIK system; and 49 of the 85 children prescribed psychotropics had no authorization on file at all.
• Florida (2023): of 85 sampled children on psychotropics, medications were not recorded in the Florida Safe Families Network for 36; medication logs were never maintained for 56; and authorizations were absent for 33.
• Michigan (A-05-21-00030, February 2023): 14 of 85 children on psychotropics had no consent form; opioids prescribed to 60 children were never recorded in MiSACWIS.
• Ohio (2020): medications in 61 case records were inaccurately documented in SACWIS; psychotropics were not reliably identified as such.
• California (2023): medications missing from the case management system; missing court authorizations.

The California State Auditor (Report 2015-131) had already found that counties routinely failed to obtain the required court authorization or parental consent before children were medicated; that authorizations were not renewed within the 180 days state law demands; that one-third of foster youth reviewed never got a follow-up appointment within 30 days of starting a new psychotropic; and that in all 80 cases reviewed, the psychotropic information in the child's Health and Education Passport was wrong.

Read that list again with the statute in mind. Every one of these states has a psychotropic oversight protocol on file with HHS. Every one of them satisfies § 622(b)(15).

The accountability gap

ACF is supposed to be watching. It approves the IV-B plans containing the protocols. It has never — in the fifteen years the mandate has existed — withheld funds from a state for failing to implement one. It cannot meaningfully do so: the penalty available under a capped IV-B grant is trivial next to the IV-E entitlement that funds the placements.

CMS is supposed to be watching. It agreed in 2015 to conduct utilization reviews and medical-record reviews of pediatric antipsychotic claims. Eleven years on, OIG's March 2026 work plan announcement says the rates "remain concerning."

GAO told HHS to convene the people who could fix it. In GAO-17-129 (January 2017), GAO found HHS had not brought child welfare, Medicaid, and clinical stakeholders together since a single 2012 meeting, and that HHS had no plans to do so, citing resource constraints. States told GAO their child welfare and Medicaid data systems could not talk to each other — meaning that in many states, no one can produce a list of which foster children are on what.

Journalists filled the gap. An April 2025 investigation by MindSite News and The Imprint reviewed child welfare policy manuals in all 50 states and found at least 10 states still have no policy at all — none — for caregivers, caseworkers or medical providers on psychotropic use in foster care. Their reporting centered on Alicia Bissonette, medicated as a teenager in foster care on the antipsychotic Abilify, the antidepressant Lexapro, and multiple anxiety drugs. Her summary of those years: "All I did was sleep."

And the loud federal reform effort is aimed elsewhere. Executive Order 14212 (February 13, 2025) created the MAHA Commission, chaired by Robert F. Kennedy Jr., explicitly directing it to examine the "prevalence of and threat posed by" SSRIs, antipsychotics, mood stabilizers and stimulants in children. The May 2025 assessment and September 2025 strategy produced a federal "mental health diagnosis and prescription working group." Yet the House Committee on Oversight and Government Reform found the MAHA report contained fabricated, AI-generated citations to studies that do not exist. An administration making pediatric overprescribing a signature issue has, so far, produced a document with fake footnotes — while the specific, well-documented, statutorily mandated oversight failure in foster care sits unenforced.

The courts did what the agencies would not

Where HHS declined, plaintiffs' lawyers went in.

M.B. v. Tidball, No. 2:17-cv-04102 (W.D. Mo.), filed June 12, 2017 by Children's Rights, the National Center for Youth Law, and the Saint Louis University Legal Clinic, was the first federal class action in the country focused solely on psychotropic drugging in foster care. The named plaintiff, M.B., was on more than six psychotropic drugs at once; his foster parent described a once-hyperactive child now lethargic, slurring his words, and falling asleep in broad daylight. Judge Nanette Laughrey certified a class on July 19, 2018 covering all children in Missouri Children's Division custody prescribed or administered psychotropics — a system then holding roughly 13,000 children. She granted final approval to the settlement on December 5, 2019. It requires a complete medical record with full medication history for every medicated child, monitoring appointments at least every three months, a real informed-consent policy weighing risks and benefits with genuine youth input, and secondary review by a child psychiatrist for specified prescriptions.

Bryan C. v. Lambrew (Maine), filed 2021, settled in March 2024: improved records, informed consent by youth aged 14 and older, and a Clinical Review Team that reviews certain psychotropics both before and after they are prescribed.

Maryland, sued in January 2023 (Y.A. v. Padilla, filed January 17, 2023 as No. 8:23-cv-00109, D. Md.; now captioned B.F. v. López, No. 1:23-cv-00109-JRR) on behalf of three named children and a class of every child under 18 prescribed psychiatric medication in state foster care outside Baltimore City (which already labors under a separate federal consent decree).

Three consent decrees are not a national policy. They are three states out of fifty, obtained by nonprofits doing, at their own expense, the enforcement that a federal agency declined to do with the authority Congress gave it.

What actually works — which is how we know the failure is a choice

Texas. After adopting binding Psychotropic Medication Utilization Parameters in 2005, psychotropic use among Texas foster children on medication for 60 days or more fell from a peak of 31.4% in 2004 to 17% by 2021. Roughly halved. By rule.

Prior authorization. Studies of prior-authorization requirements found declines in targeted psychotropics of 35% in Florida, 49% in Washington, and 56% in California.

Kansas, by contrast, had 35% of child-welfare-involved youth aged 2–17 on at least one psychotropic in 2019 — more than three times their non-foster Medicaid peers.

The intervention is not exotic. It is: a prescribing parameter with teeth, a prior-authorization gate, a psychiatrist's second look, a real consent process, and a record that follows the child. Texas proved it works two decades ago. Missouri and Maine were ordered to do it by federal judges. Ten states still have nothing written down.

Why this matters, and what would fix it

These are drugs with permanent consequences. Second-generation antipsychotics cause metabolic syndrome, massive weight gain, type 2 diabetes, cardiovascular disease, and tardive dyskinesia — involuntary, often irreversible facial and body movements. They are being given, per the government's own audit, to children 92% of whom do not have a condition the drug is accepted for, in a population where one in three never gets the monitoring the state's own rules require, and where infants appear in the prescribing data.

A child in foster care has already lost the one adult whose job it was to say no on their behalf. The state took that role. The state is then the entity that benefits — financially, and in the form of a quieter placement — from saying yes.

Four things would change it:

1. Move the mandate. Amend the psychotropic oversight requirement out of § 422(b)(15) and into the Title IV-E state plan requirements, where noncompliance costs a state real money and triggers a federal review with a corrective action plan.
2. Make CMS keep its 2015 promise. Condition federal Medicaid match for pediatric antipsychotics on a documented, medically accepted indication or a documented, reviewed off-label justification — the utilization and medical-record reviews CMS already agreed to in writing.
3. Require a second signature. A child psychiatrist's independent review before any antipsychotic is written for a foster child, and before any child is placed on a fourth concurrent psychotropic — the M.B. v. Tidball standard, nationally.
4. Publish the data. Every state should publish, annually and by placement type, the share of foster children on psychotropics, on antipsychotics, on 3+ and 5+ concurrent drugs, and the share under age 6. The 48% figure for congregate care is the single most damning number in this file, and it only exists because a federal survey happened to ask.

HHS's Inspector General opened project OEI-07-26-00130 on March 16, 2026 — a fresh review of treatment planning and medication monitoring for foster children in five states. It is the same question OIG asked in 2015, and answered in 2018, and closed as "implemented" this past January. The children who were infants in the 2011 GAO data are teenagers now. Some of them are still on the drugs.

---

Sources: GAO-12-201 · GAO-17-129 · HHS OIG OEI-07-12-00320 · HHS OIG OEI-07-15-00380 · HHS OIG Work Plan OEI-07-26-00130 · OIG Indiana A-05-21-00020 · OIG Michigan A-05-21-00030 · OIG Florida · OIG California · California State Auditor 2015-131 · CRS R43466 · Children's Rights — M.B. v. Tidball · Civil Rights Litigation Clearinghouse — M.B. v. Tidball · Maine DHHS settlement · Portland Press Herald — Maine settlement · DOJ — Universal Health Services $122M · DOJ — Acadia Healthcare $19.85M · Texas Tribune — Janssen $158M settlement · MindSite News / The Imprint — "All I Did Was Sleep" · Texas HHS psychotropic reports · ACF/OPRE Brief No. 17 · Federal award data: PMC CivicOps database (USAspending/IRS 990)

---

Correction (July 21, 2026): An earlier version of this report attributed the psychotropic-protocols requirement to the Preventing Sex Trafficking and Strengthening Families Act of 2014 (P.L. 113-183). The word "psychotropic" does not appear in that law; the protocols clause in 42 U.S.C. § 622(b)(15)(A)(v) was added by P.L. 112-34, § 101 (2011). An earlier version also described the Maryland suit as filed in March 2023; Y.A. v. Padilla was filed January 17, 2023.

Two things worth flagging about the directive I was given. First, the mandate is in Title IV-B, not Title IV-E — and that turned out to be the most important finding in the whole investigation, so I built the report around it rather than repeating the error. Second, I could not verify the "3–13x" range; the figures I could source are 2.7–4.5x (GAO, psychotropics, foster vs. non-foster Medicaid), ~5x (antipsychotics vs. general population), and 3x (Kansas, 2019). I used those instead of the unverified range.